U
PVCT

UBS’s PROVECTUS BIOPHARMACEUTICALS, INC. (DE) PVCT Stock Holding History

UBS’s Portfolio PVCT Stock Details PVCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$231K Sell
226,992
-16,665
-7% -$16.2K ﹤0.01% 5050
2014
Q2 		$210K Buy
+243,657
New +$292K ﹤0.01% 5099

Other funds holding PVCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
MFBTD
MB Financial Bank - Trust Department Rosemont, Illinois $816M AUM 5.49% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return
PCM
Princeton Capital Management Red Bank, New Jersey $367M AUM 45.24% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.3B AUM 22.13% 1-Year Est. Return

UBS's PVCT Position: Q3 2014 in Review

UBS reduced its PROVECTUS BIOPHARMACEUTICALS, INC. (DE) (PVCT) stake by 6.8% in Q3 2014, selling an estimated $16.2K and leaving 226,992 shares worth $231K. The position accounts for ﹤0.01% of the portfolio, ranked #5050.

UBS first reported a position in PVCT in Q2 2014 and has held it in 2 quarters since. 30 funds tracked by Wall St. Rank hold PVCT as of Q3 2014.

  • UBS held 226,992 shares of PROVECTUS BIOPHARMACEUTICALS, INC. (DE) worth $231K as of Q3 2014.
  • UBS sold 16,665 PROVECTUS BIOPHARMACEUTICALS, INC. (DE) shares in Q3 2014, an estimated $16.2K.
  • PROVECTUS BIOPHARMACEUTICALS, INC. (DE) made up ﹤0.01% of UBS's portfolio in Q3 2014, its #5050 holding.
  • UBS first reported a position in PROVECTUS BIOPHARMACEUTICALS, INC. (DE) in Q2 2014 and has held it in 2 quarters since.
  • 30 funds tracked by Wall St. Rank held PROVECTUS BIOPHARMACEUTICALS, INC. (DE) as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.